Goa-based Molbio Diagnostics will launch its ₹931 crore initial public offering on August 10, with a price band set at ₹768–807 per share. The company, known for its Truenat molecular testing platform, aims to fund research and manufacturing expansion. Investors should note the scheduled listing on August 17, while considering the firm's reliance on government-led health programs.
Molbio Diagnostics is heading to the capital markets, with its Initial Public Offering (IPO) scheduled to open for public subscription on August 10, 2026. The company has set a price band of ₹768 to ₹807 per share for its ₹930.7 crore issue. Investors looking to participate will need to bid for a minimum lot size of 18 equity shares, with the subscription window closing on August 12.
Based in Goa, Molbio Diagnostics provides point-of-care molecular testing solutions. Its flagship product, the Truenat platform, is designed for the rapid testing of diseases such as tuberculosis, COVID-19, and HIV. By providing PCR-based diagnostic results in under an hour, the company targets areas where access to traditional laboratory infrastructure is limited.
For the financial year ended March 31, 2026, the company reported revenue of ₹1,445.7 crore, marking an increase of 41.7% compared to the previous year. Net profit for the same period reached ₹166.6 crore, reflecting a growth of 14.8%.
The IPO consists of a fresh issue of shares worth ₹200 crore alongside an Offer for Sale (OFS) of 91.66 lakh shares by existing shareholders, including investors such as Temasek and the Motilal Oswal Group. The company plans to use ₹105.5 crore from the fresh issue to expand its research and development capabilities, including the establishment of a new Centre of Excellence through its subsidiary, Bigtec. An additional ₹72.2 crore is allocated for acquiring machinery to boost manufacturing capacity in its Goa and Visakhapatnam facilities.
While the company is scaling its operations, investors should be aware of specific business risks. The diagnostics sector is highly competitive and operates with tight margins. Furthermore, a significant portion of Molbio’s revenue is derived from bulk sales to Indian government health entities and international aid organizations. Consequently, any shifts in public health policy, changes in government procurement budgets, or a reduction in spending by global aid agencies could impact the company's future revenue streams.
Anchor investors will have the opportunity to participate in the issue on August 7, 2026. Following the closure of the IPO, the final allotment of shares is expected on August 13. The company’s shares are slated to debut on the NSE and BSE on August 17, marking a busy period for the primary market.